Patent
Human osteoclast derived cathepsin
| العنوان: | Human osteoclast derived cathepsin |
|---|---|
| Patent Number: | 6,994,978 |
| تاريخ النشر: | February 07, 2006 |
| Appl. No: | 10/726645 |
| Application Filed: | December 04, 2003 |
| مستخلص: | Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases. |
| Inventors: | Hastings, Gregg A. (Westlake Village, CA, US); Adams, Mark D. (North Potomac, MD, US); Fraser, Claire M. (Potomac, MD, US); Lee, Norman H. (Woodstock, MD, US); Kirkness, Ewen F. (Olney, MD, US); Blake, Judith A. (Laurel, MD, US); Fitzgerald, Lisa M. (Germantown, MD, US); Drake, Fred H. (Glenmore, PA, US); Gowan, Maxine (Valley Forge, PA, US) |
| Assignees: | Human Genome Sciences, Inc. (Rockville, MD, US), SmithKline Beecham Corporation (Philadelphia, PA, US) |
| Claim: | 1. A method of detecting Cathepsin O protein in a biological sample comprising: (a) contacting the biological sample with an antibody that specifically binds to a protein selected from the group consisting of: (i) amino acid residues −115 to 214 of SEQ ID NO:2; (ii) amino acid residues −100 to 214 of SEQ ID NO:2; and (iii) amino acid residues 1 to 214 of SEQ ID NO:2; and (b) wherein the binding of said antibody to said protein is idicative of the presence of Cathepsin O in a biological sample. |
| Claim: | 2. The method of claim 1 , wherein said antibody is selected from the group consisting of: (a) a monoclonal antibody; (b) a polyclonal antibody; (c) a chimeric antibody; (d) a humanized antibody; (e) a single chain antibody; and (f) an Fab fragment. |
| Claim: | 3. The method of claim 1 , wherein said antibody specifically binds to a protein consisting of amino acid residues −115 to 214 of SEQ ID NO:2. |
| Claim: | 4. The method of claim 1 , wherein said antibody specifically binds to a protein consisting of amino acids residues −100 to 214 of SEQ ID NO:2. |
| Claim: | 5. The method of claim 1 , wherein said antibody specifically binds to a protein consisting of amino acid residues 1 to 214 of SEQ ID NO:2. |
| Current U.S. Class: | 435/71 |
| Patent References Cited: | 5223408 June 1993 Goeddel et al. 5312816 May 1994 Spielvogel et al. 5374623 December 1994 Zimmerman et al. 5486623 January 1996 Zimmerman et al. 5501969 March 1996 Hastings 5552281 September 1996 Stashenko et al. 5624801 April 1997 Stashenko et al. 5656728 August 1997 Stashenko et al. 5736357 April 1998 Bromme 0 104 920 April 1984 0 110674 April 1987 0 504 938 September 1992 0 520 427 December 1994 0 111 129 September 1998 0 525420 May 1999 WO-91/01378 February 1991 WO-94/23033 October 1994 WO-95/24182 September 1995 WO-96/13523 May 1996 WO-97/35971 October 1997 WO-97/47642 December 1997 WO-98/00716 January 1998 WO-98/03651 January 1998 WO-98/08494 January 1998 WO-98/20024 May 1998 WO-98/20156 May 1998 WO-98/34117 August 1998 |
| Other References: | Barrett, et al., “L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L,” Biochem. J., 201:189 (1982). cited by other Bossard, et al., “Proteolytic activity of human osteoclast cathepsin K,” J. Biol. Chem., 271:12517-12524 (1996). cited by other Bromme, et al., “Human cathepsin 02, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution,” J. Biol. Chem., 376(6):379-384 (1995). cited by other Bromme, et al., “Peptide methyl ketones as reversible inhibitors of cysteine proteinases,” J. Enzyme Inhibition, 3:13-21 (1989). cited by other Bromme, et al., “Functional expression of human cathepsin S in Saccharomyces cerevisiae,” J. Biol. Chem., 268:4832-4838 (1993). cited by other Bromme, et al., “Potent inactivation of cathepsins S and L by peptidyl (Acyloxy)methyl ketonesa.b,” J. Biol. Chem., 375:343-347 (1994). cited by other Bromme, et al., “Peptide vinyl sulphones: a new class of potent and selective cysteine protease inhibitors,” Biochem. J., 315:85-89 (1996). cited by other Bromme, et al., “Human cathepsin 02, a matrix protein-degrading cysteine protease expressed in osteoclasts,” J. Biol. Chem., 271:2126-2132 (1996). cited by other Brown, et al., “Lymphopain, a cytotoxic T and natural killer cell-associated cysteine proteinase,” Leukemia, 12:1771-1781 (1998). cited by other Carmona, et al., “Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases,” Biochem. J., 35:8149-8157 (1996). cited by other Chagas, et al., “Inhibition of cathepsin B by its propeptide: use of overlapping peptides to identify a critical segment,” FEBS LETTS., 392:233-236 (1996). cited by other Cygler, et al., “Proregion structure of members of the papain superfamily. Mode of inhibition of enzymatic activity,” Biochemie, 79:645-652 (1997). cited by other Cygler, et al., “Structure of rat procathepsin B: mode for inhibition of cysteine protease activity by the proregion structure,” Structure, 4:405-416 (1996). cited by other D'Alessio, et al., “Expression in Escherichia coli, refolding, and purification of human procathepsin K, an osteoclast-specific protease,” Protein Expression and Purification, 15:213-220 (1999). cited by other Delaisse, et al., “Inhibition of bone resorption in culture by inhibitors of thiol proteinases,” J. Biochem., 192:365-368 (1980). cited by other Delaisse, et al., “In vivo and in vitro evidence for the involvement of cysteine proteinases in bone resorption,” Biochem. Biophys. Res. Comm., 125:441-447 (1984). cited by other Delaisse, et al., “The effects of inhibitors of cysteine—proteinases and collagenase on the resorptive activity of isolated osteoclasts,” Bone, 8:305-313 (1987). cited by other Delaisse, et al., “Collagenolytic cysteine proteinases of bone tissue,” Biochem. J., 279:167-174 (1991). cited by other Drake, et al., “Identification of a novel osteoclast selective human cysteine proteinase,” J. Bone Mineral Research, 9:5177 (A110) (1994). cited by other Drake, et al., “Cathepsin K., but not Cathepsins B, L, or S, is abundantly expressed in human osteoclasts,” J. Biol. Chem., 271:12511-12516 (1996). cited by other Duffy, et al., “Design and synthesis of diaminopyrrolidinone inhibitors of human osteoclast cathepsin K,” Bioorganic & Medicinal Chemistry, 9:1907-1910 (1999). cited by other Fox, et al., “Potent slow-binding inhibition of cathepsin B by its propeptide,” Biochem, J., 31:12571-12576 (1992). cited by other Gelb, et al., “Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency,” Science, 273:1236-1238 (1996). cited by other Gelb, et al., “Structure and chromosomal assignment of the human cathepsin K Gene,” Genomics, 41:258-262 (1997). cited by other Gelb, et al., “Cathepsin K: isolation and characterization of the murine cDNA and genomic sequence, the homolog of the human pycnodysostosis gene,” Biochem. and Mol. Med., 59:200-206 (1996). cited by other Goto, et al., “Immunohistochemical localization of cathepsins B, D and L in the rat osteoclast,” Histochemistry, 99:411-414 (1993). cited by other Goto, et al., “Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy,” Histochemistry, 101:33-40 (1994). cited by other Guay, et al., “Cloning and expression of Rhesus Monkey cathepsin K,” Bone, 25:204-209 (1999). cited by other Hill, et al., “Inhibition of bone resorption by selective inactivators of cysteine proteinases,” J. Cell Biochem., 56:118-130 (1994). cited by other Hudecki, et al., “Limited benefit to genetically dystrophic chickens from a synthetic proteinase inhibitor: Ep475,” Chemical Abstracts., 99:82493u (1983). cited by other Hudecki, et al., “Limited benefit to genetically dystrophic chickens from a synthetic proteinase inhibitor: Ep475,” J. Neurol. Sci., 60:55-66 (1983). cited by other Inaoka, et al., “Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone,” Biochem. & Biophys. Res. Comm., 206(1):89-96 (1995). cited by other James, et al., “Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents,” J. Bone & Mineral Research, 14:1562-1569 (1999). cited by other Kakegawa, et al., “Participation of cathepsin L on bone resorption,” FEBS LETTS., 321:247-250 (1993). cited by other Kane, et al., “The role of cathepsin L in malignant transformation,” Seminars in Cancer Biol., 1:127-136 (1990). cited by other Lalonde, et al., “The crystal structure of human procathepsin K.,” Biochem., 38:862-869 (1999). cited by other Lee, et al., “Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase,” Science, 239:1288-1291 (1988). cited by other Lehninger, A., “Biochemistry” 2nd ed.; Worth Publishers, Inc., New York, pp. 141 and 150 (1975). cited by other Lerner, et al., “Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by a parathyroid hormone and parathyroid hormone related peptide of malignancy,” J. Bone & Mineral Research, 4:433-439 (1992). cited by other Lerner, R.A., “Tapping the immunological repertoire to produce antibodies of predetermined specificity,” Nature, 299:592-596 (1982). cited by other Li, et al., “Characterization of mouse cathepsin K gene, the gene promoter, and the gene expression,” J. Bone & Mineral Research, 14:487-499 (1992). cited by other Li, et al., “Cloning and complete coding sequence of a novel human cathepsin expressed in glant cells of osteoclastomas,” J. Bone & Mineral Research, 10:1197-1202 (1995). cited by other Liao, et al., “Cathepsins J and K: high molecular weight cysteine proteinases from human tissues,” Biochem. Biophys. Res. Comm., 124:909-916 (1984). cited by other Maciewicz, et al., “A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen,” Biochem. J., 256:433-440 (1988). cited by other Marquis, et al., “Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K,” Bioorganic & Medicinal Chemistry, 7:581-586 (1999). cited by other Maubach, et al., “The inhibition of cathepsin S by its propeptide specificity and mechanism of action,” Eur. J. of Biochem., 250:745-750 (1997). cited by other McGrath, et al., “Crystal structure of human cathepsin K complexed with a potent inhibitor,” Nature Structural Biol., 4:105-109 (1997). cited by other McQueney, et al., “Autocatalytic activation of human cathepsin K,” J. Biol. Chem., 272(21):13955-13960 (1997). cited by other Nagler, et al., “Human cathepsin X: a cysteine protease with unique carboxypeptidase activity,” Biochemistry, 38(39):12648-12654 (1999). cited by other Ohsawa, et al., “Lysosomal cysteine and aspartic proteinases, acid phosphatase, and an endogenous cysteine proteinase inhibitor, cystatin-beta, in rat osteoclasts,” J. Histochemistry & Cytochemistry, 41(7):1075-1083 (1993). cited by other Page, et al., “Purification and characterisation of cysteine proteinases from human osteoclastomas,” Biochem. Soc. Transactions, 19:286S (1991). cited by other Rakoaczy, et al., “Detection and possible functions of a cysteine protease involved in digestion of rod outer segments by retinal pigment epithelial cells,” Invest. Ophtal. & Vis. Sci., 35:4100-4108 (1994). cited by other Shi, et al., “Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2,” FEBS LETTS., 357:129-134 (1995). cited by other Sloane, et al., “Cathepsin B and cystatins: evidence for a role in cancer progression,” Seminars in Cancer Biol., 1:137-152 (1990). cited by other Smith, et al., “Activity and deletion analysis of recombinant human cathepsin L expressed in Escherichia coli,” J. Biol. Chem., 264:20487-20495 (1989). cited by other Tezuka, et al., “Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts,” J. Biol. Chem., 269:1106-1109 (1994). cited by other Thompson, et al., “Structure-based design of non-peptide, carbohydrazide-based cathepsin K inhibitors,” Bioorganic & Medicinal Chemistry, 7:599-605 (1999). cited by other Turk, et al., “Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors,” Biol. Chem., 378:141-150 (1997). cited by other Van Noorden, et al., “Selective inhibition of cysteine proteinases by Z-Phe-A Ch2F suppresses digestion of collagen by fibroblasts and osteoclasts,” Biochemical & Biophysical Research Communications, 178(1):178-184 (1991). cited by other Veber, et al., “The new partnership of genomics and chemistry for accelerated drug development,” Chem. Biol., 1:151-156 (1997). cited by other Velasco, et al., “Human cathepsin O,” J. Biol. Chem., 43:27136-27142 (1994). cited by other Votta, et al., “Peptide aidehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo,” J. Bone & Mineral Research, 12:1396-1406 (1997). cited by other Wang, et al., “Human cathepsin F,” J. Biol. Chem., 273:32000-32008 (1998). cited by other Wiederanders, et al., “Phylogenetic conservation of cysteine proteinases,” J. Biol. Chem., 267:13708-13713 (1992). cited by other Xia, et al., “Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones,” Biol. Chem., 380:679-687 (1999). cited by other Yamamoto, et al., “Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver,” Res. Comms. in Chemical Pathology and Pharmacology, 76(1):95-112 (1992). cited by other Zhang, et al., “Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis,” J. Biol. Chem., 269(22):15918-15924 (1994). cited by other |
| Assistant Examiner: | Belyavskyi, Michail A. |
| Primary Examiner: | Chan, Christina |
| Attorney, Agent or Firm: | Human Genome Sciences, Inc. |
| رقم الانضمام: | edspgr.06994978 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |